{"product_id":"verquvo-1","title":"Verquvo","description":"\u003ch3 data-start=\"231\" data-end=\"256\"\u003eWhat is Vericiguat?\u003c\/h3\u003e\r\n\u003cp data-start=\"257\" data-end=\"596\"\u003e\u003cstrong data-start=\"257\" data-end=\"271\"\u003eVericiguat\u003c\/strong\u003e is an oral medication used as an adjunct to standard therapy in adults with symptomatic chronic heart failure with reduced ejection fraction (HFrEF) who remain at high risk of cardiovascular death or heart failure hospitalization. It is designed to improve cardiac performance by enhancing the nitric oxide–sGC–cGMP pathway.\u003c\/p\u003e\r\n\u003cp data-start=\"598\" data-end=\"735\"\u003e\u003cem data-start=\"598\" data-end=\"735\"\u003eReference: U.S. Food and Drug Administration (FDA) vericiguat prescribing information; ClinicalTrials.gov (VICTORIA trial, NCT02861534)\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"737\" data-end=\"740\"\u003e\r\n\u003ch3 data-start=\"742\" data-end=\"796\"\u003eWhat are the other popular names for Vericiguat?\u003c\/h3\u003e\r\n\u003cp data-start=\"797\" data-end=\"955\"\u003eVericiguat is marketed under the brand name \u003cstrong data-start=\"841\" data-end=\"852\"\u003eVerquvo\u003c\/strong\u003e. In clinical practice and academic literature, it is also referred to by its generic name, vericiguat.\u003c\/p\u003e\r\n\u003cp data-start=\"957\" data-end=\"998\"\u003e\u003cem data-start=\"957\" data-end=\"998\"\u003eReference: U.S. FDA; ClinicalTrials.gov\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"1000\" data-end=\"1003\"\u003e\r\n\u003ch3 data-start=\"1005\" data-end=\"1057\"\u003eWhat is the drug classification of Vericiguat?\u003c\/h3\u003e\r\n\u003cp data-start=\"1058\" data-end=\"1263\"\u003eVericiguat is classified as an \u003cstrong data-start=\"1089\" data-end=\"1140\"\u003eoral soluble guanylate cyclase (sGC) stimulator\u003c\/strong\u003e. It falls under the therapeutic category of \u003cstrong data-start=\"1185\" data-end=\"1214\"\u003eheart failure medications\u003c\/strong\u003e, specifically indicated for patients with HFrEF.\u003c\/p\u003e\r\n\u003cp data-start=\"1265\" data-end=\"1368\"\u003e\u003cem data-start=\"1265\" data-end=\"1368\"\u003eReference: U.S. FDA; National Institutes of Health (NIH); American Heart Association (AHA) guidelines\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"1370\" data-end=\"1373\"\u003e\r\n\u003ch3 data-start=\"1375\" data-end=\"1422\"\u003eWhat is the mode of action of Vericiguat?\u003c\/h3\u003e\r\n\u003cp data-start=\"1423\" data-end=\"1669\"\u003eVericiguat works by enhancing the sensitivity of soluble guanylate cyclase (sGC) to endogenous nitric oxide (NO) and by directly stimulating sGC. This dual mechanism increases the production of cyclic guanosine monophosphate (cGMP), leading to:\u003c\/p\u003e\r\n\u003cul data-start=\"1670\" data-end=\"2006\"\u003e\r\n\u003cli data-start=\"1670\" data-end=\"1747\"\u003e\n\u003cstrong data-start=\"1672\" data-end=\"1689\"\u003eVasodilation:\u003c\/strong\u003e Relaxation of vascular smooth muscle reduces afterload.\u003c\/li\u003e\r\n\u003cli data-start=\"1748\" data-end=\"1891\"\u003e\n\u003cstrong data-start=\"1750\" data-end=\"1782\"\u003eImproved Cardiac Efficiency:\u003c\/strong\u003e Lower resistance allows the heart to pump more effectively without significantly increasing oxygen demand.\u003c\/li\u003e\r\n\u003cli data-start=\"1892\" data-end=\"2006\"\u003e\n\u003cstrong data-start=\"1894\" data-end=\"1925\"\u003eReduced Cardiac Remodeling:\u003c\/strong\u003e Over time, these effects may help limit adverse structural changes in the heart.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"2008\" data-end=\"2102\"\u003e\u003cem data-start=\"2008\" data-end=\"2102\"\u003eReference: New England Journal of Medicine (NEJM) – VICTORIA trial (NEJMoa1917589); U.S. FDA\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"2104\" data-end=\"2107\"\u003e\r\n\u003ch3 data-start=\"2109\" data-end=\"2138\"\u003eHow is Vericiguat used?\u003c\/h3\u003e\r\n\u003cp data-start=\"2139\" data-end=\"2432\"\u003eVericiguat is used as an adjunct to guideline‑directed medical therapy (GDMT) in patients with symptomatic chronic HFrEF. It is prescribed for patients who continue to experience symptoms despite treatment with beta‑blockers, ACE inhibitors or ARBs, and mineralocorticoid receptor antagonists.\u003c\/p\u003e\r\n\u003cp data-start=\"2434\" data-end=\"2527\"\u003e\u003cem data-start=\"2434\" data-end=\"2527\"\u003eReference: American Heart Association (AHA) guidelines; ClinicalTrials.gov (VICTORIA trial)\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"2529\" data-end=\"2532\"\u003e\r\n\u003ch3 data-start=\"2534\" data-end=\"2605\"\u003eWhat is the recommended dosage and administration for Vericiguat?\u003c\/h3\u003e\r\n\u003cul data-start=\"2606\" data-end=\"3062\"\u003e\r\n\u003cli data-start=\"2606\" data-end=\"2855\"\u003e\n\u003cstrong data-start=\"2608\" data-end=\"2619\"\u003eDosage:\u003c\/strong\u003e\r\n\u003cul data-start=\"2624\" data-end=\"2855\"\u003e\r\n\u003cli data-start=\"2624\" data-end=\"2855\"\u003eTreatment typically begins with a lower dose (for example, \u003cstrong data-start=\"2685\" data-end=\"2706\"\u003e2.5 mg once daily\u003c\/strong\u003e) with gradual up-titration to a target maintenance dose (commonly between 10 mg and 15 mg once daily) based on clinical response and tolerability.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"2856\" data-end=\"3062\"\u003e\n\u003cstrong data-start=\"2858\" data-end=\"2877\"\u003eAdministration:\u003c\/strong\u003e\r\n\u003cul data-start=\"2882\" data-end=\"3062\"\u003e\r\n\u003cli data-start=\"2882\" data-end=\"3062\"\u003eVericiguat is taken orally in capsule form. It may be taken with or without food, but consistent dosing at the same time each day is advised for maintaining steady plasma levels.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"3064\" data-end=\"3170\"\u003e\u003cem data-start=\"3064\" data-end=\"3170\"\u003eReference: U.S. FDA vericiguat prescribing information; ClinicalTrials.gov (VICTORIA trial, NCT02861534)\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"3172\" data-end=\"3175\"\u003e\r\n\u003ch3 data-start=\"3177\" data-end=\"3240\"\u003eWhat prescribing information is important for Vericiguat?\u003c\/h3\u003e\r\n\u003cul data-start=\"3241\" data-end=\"4071\"\u003e\r\n\u003cli data-start=\"3241\" data-end=\"3451\"\u003e\n\u003cstrong data-start=\"3243\" data-end=\"3259\"\u003eIndications:\u003c\/strong\u003e\r\n\u003cul data-start=\"3264\" data-end=\"3451\"\u003e\r\n\u003cli data-start=\"3264\" data-end=\"3451\"\u003eVericiguat is indicated to reduce the risk of cardiovascular death and heart failure hospitalization in patients with chronic HFrEF who are at high risk despite optimal medical therapy.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"3452\" data-end=\"3742\"\u003e\n\u003cstrong data-start=\"3454\" data-end=\"3476\"\u003eContraindications:\u003c\/strong\u003e\r\n\u003cul data-start=\"3481\" data-end=\"3742\"\u003e\r\n\u003cli data-start=\"3481\" data-end=\"3597\"\u003eIt is contraindicated in patients with a known hypersensitivity to vericiguat or any component of the formulation.\u003c\/li\u003e\r\n\u003cli data-start=\"3600\" data-end=\"3742\"\u003eConcomitant use with nitrates or potent phosphodiesterase type 5 (PDE5) inhibitors is contraindicated due to the risk of severe hypotension.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"3743\" data-end=\"3865\"\u003e\n\u003cstrong data-start=\"3745\" data-end=\"3760\"\u003eMonitoring:\u003c\/strong\u003e\r\n\u003cul data-start=\"3765\" data-end=\"3865\"\u003e\r\n\u003cli data-start=\"3765\" data-end=\"3865\"\u003ePatients should be regularly monitored for blood pressure, renal function, and serum electrolytes.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"3866\" data-end=\"4071\"\u003e\n\u003cstrong data-start=\"3868\" data-end=\"3895\"\u003eSpecial Considerations:\u003c\/strong\u003e\r\n\u003cul data-start=\"3900\" data-end=\"4071\"\u003e\r\n\u003cli data-start=\"3900\" data-end=\"4071\"\u003eVericiguat is not recommended during pregnancy. Women of childbearing potential must use effective contraception during treatment and for a period after discontinuation.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"4073\" data-end=\"4199\"\u003e\u003cem data-start=\"4073\" data-end=\"4199\"\u003eReference: U.S. Food and Drug Administration (FDA) vericiguat label; National Institutes of Health (NIH) clinical guidelines\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"4201\" data-end=\"4204\"\u003e\r\n\u003ch3 data-start=\"4206\" data-end=\"4291\"\u003eWhat safety information, warnings, and cautions are associated with Vericiguat?\u003c\/h3\u003e\r\n\u003cul data-start=\"4292\" data-end=\"5016\"\u003e\r\n\u003cli data-start=\"4292\" data-end=\"4370\"\u003e\n\u003cstrong data-start=\"4294\" data-end=\"4318\"\u003eCommon Side Effects:\u003c\/strong\u003e\r\n\u003cul data-start=\"4323\" data-end=\"4370\"\u003e\r\n\u003cli data-start=\"4323\" data-end=\"4370\"\u003eHypotension, dizziness, headache, and anemia.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"4371\" data-end=\"5016\"\u003e\n\u003cstrong data-start=\"4373\" data-end=\"4397\"\u003eWarnings \u0026amp; Cautions:\u003c\/strong\u003e\r\n\u003cul data-start=\"4402\" data-end=\"5016\"\u003e\r\n\u003cli data-start=\"4402\" data-end=\"4566\"\u003e\n\u003cstrong data-start=\"4404\" data-end=\"4420\"\u003eHypotension:\u003c\/strong\u003e Patients are at risk for low blood pressure, especially during dose titration. Advise slow position changes and monitor blood pressure closely.\u003c\/li\u003e\r\n\u003cli data-start=\"4569\" data-end=\"4632\"\u003e\n\u003cstrong data-start=\"4571\" data-end=\"4586\"\u003eFetal Harm:\u003c\/strong\u003e Vericiguat is contraindicated in pregnancy.\u003c\/li\u003e\r\n\u003cli data-start=\"4635\" data-end=\"4858\"\u003e\n\u003cstrong data-start=\"4637\" data-end=\"4659\"\u003eDrug Interactions:\u003c\/strong\u003e\r\n\u003cul data-start=\"4666\" data-end=\"4858\"\u003e\r\n\u003cli data-start=\"4666\" data-end=\"4750\"\u003eConcomitant use with nitrates or PDE5 inhibitors may lead to severe hypotension.\u003c\/li\u003e\r\n\u003cli data-start=\"4755\" data-end=\"4858\"\u003eCoadministration with other antihypertensives may result in additive blood pressure–lowering effects.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"4861\" data-end=\"5016\"\u003e\n\u003cstrong data-start=\"4863\" data-end=\"4882\"\u003eOrgan Function:\u003c\/strong\u003e Caution is advised in patients with impaired renal or hepatic function; these patients require dose adjustments and close monitoring.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"5018\" data-end=\"5141\"\u003e\u003cem data-start=\"5018\" data-end=\"5141\"\u003eReference: U.S. FDA; New England Journal of Medicine (NEJM) – VICTORIA trial; American Heart Association (AHA) guidelines\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"5143\" data-end=\"5146\"\u003e\r\n\u003ch3 data-start=\"5148\" data-end=\"5214\"\u003eWhat drug interactions should be considered with Vericiguat?\u003c\/h3\u003e\r\n\u003cul data-start=\"5215\" data-end=\"5679\"\u003e\r\n\u003cli data-start=\"5215\" data-end=\"5383\"\u003e\n\u003cstrong data-start=\"5217\" data-end=\"5280\"\u003eNitrates and PDE5 Inhibitors (e.g., Sildenafil, Tadalafil):\u003c\/strong\u003e\r\n\u003cul data-start=\"5285\" data-end=\"5383\"\u003e\r\n\u003cli data-start=\"5285\" data-end=\"5383\"\u003eThese are contraindicated when used with vericiguat because of the risk of profound hypotension.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"5384\" data-end=\"5521\"\u003e\n\u003cstrong data-start=\"5386\" data-end=\"5420\"\u003eOther Antihypertensive Agents:\u003c\/strong\u003e\r\n\u003cul data-start=\"5425\" data-end=\"5521\"\u003e\r\n\u003cli data-start=\"5425\" data-end=\"5521\"\u003eConcurrent use may enhance blood pressure–lowering effects and necessitate dosage adjustments.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"5522\" data-end=\"5679\"\u003e\n\u003cstrong data-start=\"5524\" data-end=\"5560\"\u003eAgents Affecting Renal Function:\u003c\/strong\u003e\r\n\u003cul data-start=\"5565\" data-end=\"5679\"\u003e\r\n\u003cli data-start=\"5565\" data-end=\"5679\"\u003eDrugs that impair renal hemodynamics may affect the pharmacokinetics of vericiguat; close monitoring is advised.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"5681\" data-end=\"5760\"\u003e\u003cem data-start=\"5681\" data-end=\"5760\"\u003eReference: U.S. FDA vericiguat label; Clinical Pharmacology Reviews on PubMed\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"5762\" data-end=\"5765\"\u003e\r\n\u003ch3 data-start=\"5767\" data-end=\"5861\"\u003eWhere can I find additional clinical evidence and detailed information about Vericiguat?\u003c\/h3\u003e\r\n\u003cp data-start=\"5862\" data-end=\"5956\"\u003eFor further details on clinical studies, dosing guidelines, and safety monitoring, refer to:\u003c\/p\u003e\r\n\u003cul data-start=\"5957\" data-end=\"6378\"\u003e\r\n\u003cli data-start=\"5957\" data-end=\"6045\"\u003e\n\u003cstrong data-start=\"5959\" data-end=\"6011\"\u003eU.S. Food and Drug Administration (FDA) Website:\u003c\/strong\u003e \u003ca href=\"https:\/\/www.fda.gov\/\" target=\"_new\" rel=\"noopener\" data-start=\"6012\" data-end=\"6043\"\u003eFDA.gov\u003c\/a\u003e\n\u003c\/li\u003e\r\n\u003cli data-start=\"6046\" data-end=\"6154\"\u003e\n\u003cstrong data-start=\"6048\" data-end=\"6102\"\u003eClinicalTrials.gov – VICTORIA Trial (NCT02861534):\u003c\/strong\u003e \u003ca href=\"https:\/\/clinicaltrials.gov\/\" target=\"_new\" rel=\"noopener\" data-start=\"6103\" data-end=\"6152\"\u003eClinicalTrials.gov\u003c\/a\u003e\n\u003c\/li\u003e\r\n\u003cli data-start=\"6155\" data-end=\"6291\"\u003e\n\u003cstrong data-start=\"6157\" data-end=\"6229\"\u003eNew England Journal of Medicine (NEJM) – VICTORIA Trial Publication:\u003c\/strong\u003e \u003ca target=\"_new\" rel=\"noopener\" data-start=\"6230\" data-end=\"6289\"\u003eNEJM\u003c\/a\u003e\n\u003c\/li\u003e\r\n\u003cli data-start=\"6292\" data-end=\"6378\"\u003e\n\u003cstrong data-start=\"6294\" data-end=\"6342\"\u003eAmerican Heart Association (AHA) Guidelines:\u003c\/strong\u003e \u003ca href=\"https:\/\/www.heart.org\/\" target=\"_new\" rel=\"noopener\" data-start=\"6343\" data-end=\"6378\"\u003eHeart.org\u003c\/a\u003e\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003chr data-start=\"6380\" data-end=\"6383\"\u003e\r\n\u003ch3 data-start=\"6385\" data-end=\"6405\"\u003eFinal Thoughts\u003c\/h3\u003e\r\n\u003cp data-start=\"6406\" data-end=\"6971\"\u003e\u003cstrong data-start=\"6406\" data-end=\"6442\"\u003eVericiguat (marketed as Verquvo)\u003c\/strong\u003e is an important advancement in the management of chronic heart failure with reduced ejection fraction. By stimulating soluble guanylate cyclase and increasing cGMP levels, vericiguat promotes vasodilation and improves cardiac output, thereby reducing the risk of hospitalization and cardiovascular death. Due to its potential to lower blood pressure and its contraindications with certain agents (such as nitrates and PDE5 inhibitors), vericiguat must be used with careful monitoring under the guidance of a healthcare provider.\u003c\/p\u003e\r\n\u003cp data-start=\"6973\" data-end=\"7197\"\u003e\u003cem data-start=\"6973\" data-end=\"7197\"\u003eDisclaimer: This information is provided for educational purposes only and should not replace professional medical advice. Always consult with your healthcare provider before initiating or modifying any medication regimen.\u003c\/em\u003e\u003c\/p\u003e","brand":"EZ Chemist","offers":[{"title":"2.5 mg","offer_id":51736357798171,"sku":"Verquvo- 2.5 mg-1","price":43.14,"currency_code":"USD","in_stock":true},{"title":"5mg","offer_id":51736357830939,"sku":"Verquvo-5mg-1","price":67.2,"currency_code":"USD","in_stock":true},{"title":"10mg","offer_id":51736357863707,"sku":"Verquvo-10mg-1","price":78.3,"currency_code":"USD","in_stock":true}],"url":"https:\/\/ezchemist.com\/products\/verquvo-1","provider":"EZ Chemist","version":"1.0","type":"link"}